Valuation: Abbott Laboratories (Pakistan) Limited

Market Cap 91.14B 328M 287M 265M 243M 461M 31.56B 469M 3.16B 1.24B 15.42B 1.23B 1.2B 53.16B P/E 2024
23.2x
P/E 2025 -
Enterprise Value 91.14B 328M 287M 265M 243M 461M 31.56B 469M 3.16B 1.24B 15.42B 1.23B 1.2B 53.16B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
19.95%
Yield 2024 *
-
Yield 2025 3.81%
1 day+0.46%
1 week-6.65%
Current month-5.43%
1 month+4.73%
3 months-3.36%
6 months-22.44%
Current year-11.35%
1 week 920.01
Extreme 920.01
990
1 month 906
Extreme 906
1,029
Current year 821
Extreme 821
1,274
1 year 821
Extreme 821
1,304
3 years 330
Extreme 330
1,310
5 years 330
Extreme 330
1,310
10 years 302.1
Extreme 302.1
1,310
Manager TitleAgeSince
Chief Executive Officer - 01/04/2016
Director of Finance/CFO - 01/11/2019
Chief Operating Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member - 01/03/2009
Director/Board Member - 04/06/2014
Chairman - 30/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
+0.46%-6.65%-14.60%+127.01% 326M
+0.35%-4.87%+49.87%+158.67% 1,028B
-2.69%-6.22%+59.19%+55.29% 611B
+0.44%-3.41%+30.97%+81.05% 432B
+0.98%-1.40%+29.49%+23.12% 323B
-0.34%-3.10%+27.00%+43.66% 277B
+1.63%-11.76%+19.72%+23.20% 257B
+3.39%+2.29%-23.68%-38.33% 217B
+0.86%-2.63%+22.50%+57.27% 192B
+1.28%-3.03%+20.76%+69.98% 161B
Average +0.86%-5.07%+22.12%+60.09% 349.87B
Weighted average by Cap. +0.46%-5.52%+35.85%+77.59%

Financials

2024 2025
Net sales 68.18B 245M 215M 198M 182M 345M 23.61B 351M 2.36B 927M 11.54B 921M 901M 39.77B 75.4B 271M 237M 219M 201M 381M 26.11B 388M 2.61B 1.03B 12.76B 1.02B 997M 43.98B
Net income 5.23B 18.84M 16.47M 15.19M 13.97M 26.46M 1.81B 26.91M 181M 71.16M 886M 70.74M 69.19M 3.05B 7.97B 28.67M 25.07M 23.12M 21.26M 40.27M 2.76B 40.96M 276M 108M 1.35B 108M 105M 4.65B
Net Debt - -
Logo Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
Employees
1,380
Date Price Change Volume
15/07/26 PKR 930.91 +0.46% 7,755
14/07/26 PKR 926.63 -2.50% 14,501
13/07/26 PKR 950.35 -1.36% 48,683
10/07/26 PKR 963.50 -0.14% 15,160
09/07/26 PKR 964.81 -0.23% 21,681
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
930.91
Average target price
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABOT Stock